FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028931110> ?p ?o ?g. }

• W2028931110 endingPage "1945" @default.
• W2028931110 startingPage "1936" @default.
• W2028931110 abstract "Background: Daptomycin is most commonly used as a second-line treatment. Previous studies have not differentiated the effect of prior antibiotic therapy on daptomycin clinical outcomes. Objectives: The primary objective of this study was to compare clinical outcomes of patients treated with daptomycin as first-line therapy versus after prior antibiotic therapy (specifically, vancomycin). A secondary objective was to identify other factors associated with the clinical failure of daptomycin therapy. Methods: This was a retrospective cohort study using data from a postlabeling registry database. The effects of relevant patient characteristics on the clinical outcome of individuals treated for Staphylococcus aureus infections with daptomycin were examined in an unblinded approach using univariate and multivariate analyses. Only patients with an evaluable clinical outcome (ie, cure, improvement, failure) and culture-confirmed S aureus infection were included in the analysis cohort. Results: Of 1227 clinically evaluable patients, 250 (20%) received daptomycin as first-line therapy and 977 (80%) received daptomycin after other prior antibiotic therapy. Overall, 53% of patients were male; 64% were aged 31 to 65 years and 26% were aged ≥66 years. Race information was collected beginning in 2007; of the patients studied, 71% were white and 18% were black. The initial daptomycin dose (mean [SD]) overall was 5.1 (1.1) mg/kg and was highest for patients with endocarditis (5.9 [1.2] mg/kg) and lowest for those with uncomplicated skin and skin structure infections (4.4 [0.9] mg/kg). Clinical success, defined as an outcome of cured or improved at the end of daptomycin therapy, was reported for 1140 (93%) of the 1227 evaluable patients. The clinical success rates for first-line therapy with daptomycin and after prior antibiotics were both 93%. Using univariate analysis, 8 variables were associated with clinical failure (receipt of daptomycin in an intensive care unit setting, severe renal dysfunction [creatinine clearance <30 mL/min], dialysis, diabetes mellitus (DM), concomitant antibiotics, bacteremia, endocarditis, and failure of prior vancomycin therapy) and 3 with clinical success (outpatient daptomycin therapy and complicated and uncomplicated skin and skin structure infections). Using the stepwise multivariate regression analysis, only the presence of endocarditis (odds ratio [OR] = 2.56; 95% CI, 1.18–5.54; P = 0.017), bacteremia (OR = 1.77; 95% CI, 1.04–3.02; P = 0.037), severe renal dysfunction (OR = 1.78; 95% CI, 1.05–3.03; P = 0.034), and DM (OR = 1.79; 95% CI, 1.10–2.93; P = 0.02) were identified as factors independently associated with clinical failure of daptomycin therapy. Of the remaining patients, 9% were aged 18 to 30 years and 0.7% were aged 12 to 17 years. Conclusions: In this retrospective study, after controlling for clinical factors that are associated with suboptimal outcomes, clinical outcomes with daptomycin did not differ whether it was used as first-line therapy or after other antibiotics. Endocarditis, bacteremia, severe renal dysfunction, and DM were associated with higher rates of clinical failure of daptomycin treatment." @default.
• W2028931110 created "2016-06-24" @default.
• W2028931110 creator A5010993325 @default.
• W2028931110 creator A5017445754 @default.
• W2028931110 creator A5034690632 @default.
• W2028931110 creator A5079682989 @default.
• W2028931110 creator A5084049528 @default.
• W2028931110 date "2009-09-01" @default.
• W2028931110 modified "2023-10-06" @default.
• W2028931110 title "Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: A retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience" @default.
• W2028931110 cites W1604093565 @default.
• W2028931110 cites W1967504109 @default.
• W2028931110 cites W1974207408 @default.
• W2028931110 cites W1977676640 @default.
• W2028931110 cites W1996504640 @default.
• W2028931110 cites W2002249283 @default.
• W2028931110 cites W2007568044 @default.
• W2028931110 cites W2014605891 @default.
• W2028931110 cites W2033305060 @default.
• W2028931110 cites W2040800443 @default.
• W2028931110 cites W2041975350 @default.
• W2028931110 cites W2045768636 @default.
• W2028931110 cites W2066038082 @default.
• W2028931110 cites W2093345619 @default.
• W2028931110 cites W2095215130 @default.
• W2028931110 cites W2096081339 @default.
• W2028931110 cites W2096541421 @default.
• W2028931110 cites W2099274786 @default.
• W2028931110 cites W2116262659 @default.
• W2028931110 cites W2116954897 @default.
• W2028931110 cites W2124285733 @default.
• W2028931110 cites W2125733555 @default.
• W2028931110 cites W2133902131 @default.
• W2028931110 cites W2135845389 @default.
• W2028931110 cites W2140643555 @default.
• W2028931110 cites W2144963218 @default.
• W2028931110 cites W2146333310 @default.
• W2028931110 cites W2156794613 @default.
• W2028931110 cites W2156980227 @default.
• W2028931110 cites W2157018267 @default.
• W2028931110 doi "https://doi.org/10.1016/j.clinthera.2009.09.012" @default.
• W2028931110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19843483" @default.
• W2028931110 hasPublicationYear "2009" @default.
• W2028931110 type Work @default.
• W2028931110 sameAs 2028931110 @default.
• W2028931110 citedByCount "52" @default.
• W2028931110 countsByYear W20289311102012 @default.
• W2028931110 countsByYear W20289311102013 @default.
• W2028931110 countsByYear W20289311102014 @default.
• W2028931110 countsByYear W20289311102015 @default.
• W2028931110 countsByYear W20289311102016 @default.
• W2028931110 countsByYear W20289311102017 @default.
• W2028931110 countsByYear W20289311102018 @default.
• W2028931110 countsByYear W20289311102019 @default.
• W2028931110 countsByYear W20289311102020 @default.
• W2028931110 countsByYear W20289311102021 @default.
• W2028931110 crossrefType "journal-article" @default.
• W2028931110 hasAuthorship W2028931110A5010993325 @default.
• W2028931110 hasAuthorship W2028931110A5017445754 @default.
• W2028931110 hasAuthorship W2028931110A5034690632 @default.
• W2028931110 hasAuthorship W2028931110A5079682989 @default.
• W2028931110 hasAuthorship W2028931110A5084049528 @default.
• W2028931110 hasConcept C126322002 @default.
• W2028931110 hasConcept C141071460 @default.
• W2028931110 hasConcept C144301174 @default.
• W2028931110 hasConcept C167135981 @default.
• W2028931110 hasConcept C201903717 @default.
• W2028931110 hasConcept C2778651397 @default.
• W2028931110 hasConcept C2778980435 @default.
• W2028931110 hasConcept C2779443120 @default.
• W2028931110 hasConcept C2779489039 @default.
• W2028931110 hasConcept C38180746 @default.
• W2028931110 hasConcept C501593827 @default.
• W2028931110 hasConcept C523546767 @default.
• W2028931110 hasConcept C54355233 @default.
• W2028931110 hasConcept C71924100 @default.
• W2028931110 hasConcept C72563966 @default.
• W2028931110 hasConcept C86803240 @default.
• W2028931110 hasConcept C89423630 @default.
• W2028931110 hasConceptScore W2028931110C126322002 @default.
• W2028931110 hasConceptScore W2028931110C141071460 @default.
• W2028931110 hasConceptScore W2028931110C144301174 @default.
• W2028931110 hasConceptScore W2028931110C167135981 @default.
• W2028931110 hasConceptScore W2028931110C201903717 @default.
• W2028931110 hasConceptScore W2028931110C2778651397 @default.
• W2028931110 hasConceptScore W2028931110C2778980435 @default.
• W2028931110 hasConceptScore W2028931110C2779443120 @default.
• W2028931110 hasConceptScore W2028931110C2779489039 @default.
• W2028931110 hasConceptScore W2028931110C38180746 @default.
• W2028931110 hasConceptScore W2028931110C501593827 @default.
• W2028931110 hasConceptScore W2028931110C523546767 @default.
• W2028931110 hasConceptScore W2028931110C54355233 @default.
• W2028931110 hasConceptScore W2028931110C71924100 @default.
• W2028931110 hasConceptScore W2028931110C72563966 @default.
• W2028931110 hasConceptScore W2028931110C86803240 @default.
• W2028931110 hasConceptScore W2028931110C89423630 @default.
• W2028931110 hasIssue "9" @default.
• W2028931110 hasLocation W20289311101 @default.

• next